About Richard Knight

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.

Safety Must Be Prioritized In Drugs for Cancer

Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several  years. Though there is a [...]

By |2018-07-11T10:00:27+00:00May 16th, 2018|Press|Comments Off on Safety Must Be Prioritized In Drugs for Cancer

Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients. Dr Richard Knight of Alderley Park-based ApconiX told last month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to [...]

By |2018-07-11T10:12:48+00:00March 27th, 2018|Toxicology|Comments Off on Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Accelerating Cancer Drug Development

Accelerating Cancer Drug Development -From target to patients, BioNow will be hosting this event at Alderley Park on the 27th of February 2018. Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst [...]

By |2018-07-11T11:58:57+00:00February 27th, 2018|Events|Comments Off on Accelerating Cancer Drug Development

XenoGesis and Sygnature Discovery to Host Meeting

XenoGesis is teaming up with Sygnature Discovery and DMDG to host the forthcoming meeting on predictive toxicology in Discovery DMPK. The one-day meeting will be held at BioCity, Nottingham on Thursday 22nd March 2018. The meeting will provide a forum for the exchange of ideas between members of the DMPK and toxicology research communities. The event will bring together talks from thought [...]

By |2018-07-11T12:06:23+00:00February 22nd, 2018|Events|Comments Off on XenoGesis and Sygnature Discovery to Host Meeting

Attitude Toward Safety in Needs to Change

A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues [...]

By |2018-06-27T16:32:28+00:00February 20th, 2018|Press|Comments Off on Attitude Toward Safety in Needs to Change

ApconiX Achieves Five-Fold Turnover Boost

The business has just received the accolade of Start-Up of the Year at the 17th awards hosted by BioNow, the northern England bio-medical and life sciences membership organisation. The company’s early success is based on delivering expertise in safety toxicology and ion channel electrophysiology to a changing pharmaceutical sector, in which more companies are outsourcing [...]

By |2018-07-11T14:31:30+00:00December 7th, 2017|Press|Comments Off on ApconiX Achieves Five-Fold Turnover Boost

Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure? 

Abstract: We have previously reported the profile of target organs (defined as organs showing histopathological changes) in rodent and non-rodent toxicity studies conducted prior to first-time-in-man (FTiM) for 77 AstraZeneca candidate drugs (CDs). Here, we test the assumption that toxicity is exacerbated by dosing duration by comparing the incidence and severity of target organ toxicities in these [...]

By |2018-06-27T16:39:23+00:00December 1st, 2015|Toxicology, Publications|Comments Off on Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure? 

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors.

Abstract: Purpose AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients. Experimental design In this Phase I study, patients received intravenous AZD7762 on days 1 and 8 of a 14-day run-in cycle (cycle 0; AZD7762 [...]

By |2018-06-27T17:03:44+00:00March 20th, 2014|Toxicology, Publications|Comments Off on Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors.